Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.36 USD | -0.58% | -4.16% | -42.80% |
May. 15 | QuidelOrtho Opens New Distribution Center in Pedricktown, NJ | CI |
May. 14 | Activist Jana Partners built position in QuidelOrtho in first quarter, sources say | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.80% | 2.85B | C+ | ||
-21.19% | 17.75B | A | ||
+21.31% | 1.92B | - | ||
-5.07% | 1.58B | - | ||
-17.46% | 952M | - | ||
-22.39% | 888M | - | C- | |
+4.34% | 828M | - | ||
-26.54% | 611M | B+ | ||
+19.58% | 591M | C+ | ||
-.--% | 482M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QDEL Stock
- Ratings QuidelOrtho Corporation